Sanofi, Regeneron expand tie-up with $8 billion drug-development deal, settle legal dispute
SNY•Sanofi will pay Regeneron $1 billion upfront and up to $7 billion in milestones to develop four drugs, with the companies sharing development costs and future profits. They also settled prior litigation.
1. Deal terms
Sanofi and Regeneron said they will develop four antibody drugs and settle prior litigation. Sanofi will pay $1 billion upfront and up to $7 billion in milestone payments, while the companies will equally share development costs and future profits. Regeneron will lead research, and Sanofi will handle global sales if the drugs are approved.
2. Pipeline and outlook
The drugs target type 2 inflammation pathways. One, REGN20423, is in early-stage testing for atopic dermatitis; the other three are expected to begin clinical testing in 2027. Analysts broadly viewed the deal positively, while some said Sanofi still needs to strengthen its pipeline ahead of Dupixent's patent loss later this decade. Dupixent accounted for 36% of Sanofi's nearly 44 billion euros in 2025 sales.
